



## Webinar Invitation

### **3<sup>rd</sup> Safe Prescribing Event:** *Addressing Concurrent Opioid and CNS Depressant Medications*

July 21, 2020  
1:00– 2:30 pm Eastern Standard Time

Please Join James W. Carroll, Director of National Drug Control Policy

#### **Scheduled Speakers:**

- James W. Carroll, JD, Director, White House Office of National Drug Control Policy
- LCDR Joshua Hunt, PharmD, MPH, Policy Analyst, Public Health, Education and Treatment, ONDCP
- LCDR Mark Liberatore, PharmD, RAC, Deputy Director for Safety, Division of Anesthesiology, Addiction Medicine, and Pain Medicine, FDA
- Wilson Compton, MD, MPE, Deputy Director, National Institute on Drug Abuse, NIH
- Marta Sokolowska, Ph.D., Associate Director for Controlled Substances, Center for Drug Evaluation and Research, FDA
- Christina Mikosz, MD, MPH, FACP, Division of Overdose Prevention, National Center for Injury Prevention and Control, CDC
- Friedhelm Sandbrink, MD, National Program Director for Pain Management, Specialty Care Services, VHA
- Fuad Issa, MD, Chief, Risk Reduction, Psychological Health Center of Excellence, Defense Health Agency
- CAPT Edward Simmer, MD, MPH, Chief Medical Officer, TRICARE Health Plan, Defense Health Agency

The White House Office of National Drug Control Policy (ONDCP) is leading an effort to highlight the availability of clinical tools for safe prescribing of opioids and CNS depressants. During this webinar, federal officials will share the risks associated with the co-use of Opioids and CNS depressants. Safe prescribing includes appropriate patient selection, medication selection and dosage, as well as coordination of prescriptions between multiple providers (if applicable) to limit the co-prescribing and scenarios of co-use of opioids and CNS depressant medications to only clinically necessary situations.

The ONDCP Public Health, Education and Treatment (PHET) Task Force hopes to utilize this webinar to communicate the Trump Administration's continued dedication to safe prescribing practices. The National Drug Control Strategy emphasizes the importance of safe prescribing education throughout the medical community and is a priority item for the PHET component.

**Please Register By 7/14:** Participants will receive instructions on accessing the conference after RSVP'ing to the following link: <https://ems9.intellor.com/?do=register&t=1&p=901691>

**You may share this invitation with colleagues. Space is limited, so register early. We encourage those from the same organization to dial in together when possible.**